Low Density Lipoprotein Receptor
Introduction
Section titled “Introduction”The low-density lipoprotein receptor (LDLR) is a crucial protein responsible for regulating cholesterol levels in the blood. Cholesterol, a waxy, fat-like substance, is essential for building healthy cells, but high levels of low-density lipoprotein (LDL) cholesterol, often referred to as “bad” cholesterol, can lead to serious health problems. TheLDLR gene provides instructions for making the LDLR protein, which plays a central role in the body’s cholesterol metabolism.
Biologically, the LDLR protein is found on the surface of cells, primarily in the liver. Its main function is to bind to LDL particles circulating in the bloodstream. Once bound, the receptor-LDL complex is internalized into the cell, where the LDL particle is broken down and its cholesterol is used or stored. This process effectively removes excess LDL cholesterol from the blood, preventing its accumulation in arteries.
Clinically, the proper functioning of the LDLRis vital for maintaining cardiovascular health. Mutations or variations in theLDLRgene can impair the receptor’s ability to clear LDL cholesterol from the blood. This leads to significantly elevated levels of LDL cholesterol, a condition known as familial hypercholesterolemia (FH). Individuals with FH are at a substantially increased risk of developing early-onset heart disease, including atherosclerosis, heart attacks, and strokes, due to the chronic buildup of cholesterol plaques in their arteries.
The social importance of understanding the LDLRand its role in cholesterol regulation is profound. Cardiovascular diseases, often driven by high LDL cholesterol, are a leading cause of morbidity and mortality worldwide. Knowledge ofLDLR function and genetic variations has been instrumental in the diagnosis of inherited cholesterol disorders, the development of screening programs, and the creation of effective therapeutic strategies. Treatments such as statins and PCSK9 inhibitors, which either reduce cholesterol synthesis or enhance LDLR activity, directly leverage our understanding of this receptor to improve public health outcomes and extend healthy lifespans globally.
Limitations
Section titled “Limitations”Methodological and Statistical Constraints
Section titled “Methodological and Statistical Constraints”Many studies investigating the low-density lipoprotein receptor, often focusing on the_LDLR_gene, are subject to inherent methodological and statistical limitations that can influence the robustness and generalizability of their findings. Smaller sample sizes in some cohorts, particularly for rare variants or specific populations, can lead to insufficient statistical power, increasing the risk of both false positives and false negatives. This can result in effect-size inflation, where the observed genetic associations appear stronger than they truly are, making replication across independent cohorts crucial but often challenging, leading to gaps in confirming initial findings. Furthermore, cohort bias, arising from the specific characteristics or recruitment methods of study participants, can limit the applicability of results to broader populations.
The interpretation of genetic associations, such as those involving _LDLR_ variants like rs6511720 , can also be impacted by these constraints. Associations found in underpowered studies may not hold up in larger meta-analyses, highlighting the need for extensive validation. Without consistent replication across diverse and sufficiently powered studies, the true impact of specific genetic variations on low-density lipoprotein receptor function and related phenotypes, such as cholesterol levels, remains uncertain. This necessitates a cautious approach when translating research findings into clinical or personalized health recommendations.
Generalizability and Phenotypic Complexity
Section titled “Generalizability and Phenotypic Complexity”Research on the low-density lipoprotein receptor often faces challenges related to generalizability, primarily due to ancestry-specific genetic architectures and insufficient representation of diverse populations in genetic studies. The vast majority of genetic research has historically focused on individuals of European descent, meaning that findings regarding_LDLR_variants or their associated phenotypes may not accurately reflect the genetic landscape or disease risk in other ancestral groups. This ancestral bias can lead to disparities in understanding genetic predispositions and therapeutic responses across different global populations.
Moreover, accurately measuring and defining complex phenotypes related to _LDLR_function, such as lipid profiles or cardiovascular disease risk, presents its own set of challenges. Phenotypic measurement concerns can arise from varying diagnostic criteria, different laboratory assays, and environmental factors that fluctuate over time, all of which can introduce noise and variability into research data. These inconsistencies make it difficult to precisely link specific genetic variations in_LDLR_to a clear and consistent biological outcome, complicating efforts to fully elucidate the gene’s role in health and disease.
Environmental and Genetic Interactions
Section titled “Environmental and Genetic Interactions”The functional implications of the low-density lipoprotein receptor are not solely determined by genetics but are significantly modulated by a complex interplay with environmental factors, leading to considerable gene–environment confounders. Lifestyle choices, dietary patterns, physical activity levels, and exposure to various environmental stressors can profoundly influence lipid metabolism and the expression or activity of the_LDLR_ gene. Failure to adequately account for these non-genetic factors in research designs can obscure the true genetic effects, making it difficult to isolate the precise contribution of _LDLR_ variants to a given phenotype.
This intricate interaction also contributes to the phenomenon of “missing heritability,” where the collective genetic variants identified through genome-wide association studies (GWAS) only explain a fraction of the observed heritable variation in complex traits like cholesterol levels or cardiovascular disease risk. The remaining knowledge gaps regarding_LDLR_’s full genetic architecture likely stem from undiscovered rare variants, complex epigenetic modifications, and the numerous gene-gene and gene-environment interactions that are difficult to model comprehensively. Understanding these multifaceted influences is crucial for a complete picture of _LDLR_’s role, moving beyond single-gene analyses to more holistic systems biology approaches.
Variants
Section titled “Variants”Genetic variations play a crucial role in regulating lipid metabolism and influencing the function of the low-density lipoprotein receptor (LDLR), which is essential for clearing cholesterol from the bloodstream. Several variants across various genes impact the production, processing, and clearance of lipoproteins, thereby affecting the availability of ligands forLDLR or its own activity. These genes include those directly involved in lipid synthesis and breakdown, as well as those with more indirect regulatory or immune-related roles.
Key enzymes and regulatory proteins in lipid and glucose metabolism often harbor variants that significantly alter lipoprotein profiles. For instance, theLPLgene, encoding Lipoprotein Lipase, is critical for hydrolyzing triglycerides in chylomicrons and very-low-density lipoproteins (VLDL); thers13702 variant can influence this activity, affecting triglyceride clearance and indirectly impacting LDL particle composition and the efficiency ofLDLR binding. [1] Similarly, the rs1260326 variant in GCKR, which codes for Glucokinase Regulatory Protein, is strongly associated with elevated triglyceride levels and can influence hepatic lipogenesis, thereby altering VLDL production—a precursor to LDL—and potentially affectingLDLR substrate availability. [2] Another crucial regulator is MLXIPL, a transcription factor that controls de novo lipogenesis; its rs3812316 variant impacts triglyceride synthesis and VLDL secretion, which can indirectly influenceLDLRfunction by altering circulating lipoprotein levels.[3] Furthermore, the rs247617 variant located near HERPUD1 and CETP is relevant because CETP(Cholesteryl Ester Transfer Protein) mediates the exchange of cholesteryl esters and triglycerides between lipoproteins, and variants affecting its activity can directly impact LDL and HDL cholesterol levels, thus influencing the overall lipoprotein environment thatLDLR operates within. [4]
Beyond core metabolic enzymes, other genes contribute to lipid homeostasis through diverse mechanisms. The DOCK7 gene, despite its primary role in neuronal development, has variants like rs12239736 that are associated with triglyceride levels, suggesting broader metabolic functions that could indirectly affect lipoprotein profiles andLDLR activity. [5] Pseudogenes, such as TRIB1AL and APOC1P1, can also play a role; the rs28601761 in TRIB1AL (a pseudogene of TRIB1, a known lipid regulator) and rs5112 in APOC1P1 (a pseudogene of APOC1, involved in HDL and VLDL metabolism) might influence the expression or function of their respective functional genes or other related pathways, thereby modulating lipoprotein composition and affecting how these particles interact withLDLR. [6] The ZPR1 gene, involved in RNA binding and cell proliferation, also features the rs964184 variant; while less directly tied to lipid metabolism, its general cellular roles may have downstream effects on metabolic pathways or cell signaling relevant to lipoprotein processing or the regulation ofLDLR. [7]
Further genetic variations in non-coding regions or immune-related genes can also impact lipid metabolism. The rs559220724 variant in LINC02702, a long intergenic non-coding RNA, could influence the expression of nearby genes involved in metabolic processes, potentially affecting lipid synthesis or lipoprotein remodeling in ways that impactLDLR function. [8] Similarly, the rs6882076 variant located near TIMD4 and HAVCR1, genes involved in immune responses, highlights the intricate connection between inflammation and lipid metabolism. Inflammatory processes are known to modulate LDLRexpression and activity, meaning variants in these regions could indirectly affect lipoprotein profiles andLDLR function by influencing inflammatory pathways. [9]Collectively, these diverse genetic variants underscore the complex regulatory network that governs lipoprotein metabolism and its crucial link toLDLR activity, ultimately influencing an individual’s risk for dyslipidemia.
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs964184 | ZPR1 | very long-chain saturated fatty acid measurement coronary artery calcification vitamin K measurement total cholesterol measurement triglyceride measurement |
| rs28601761 | TRIB1AL | mean corpuscular hemoglobin concentration glomerular filtration rate coronary artery disease alkaline phosphatase measurement YKL40 measurement |
| rs5112 | APOC1P1, APOC1P1 | body height level of apolipoprotein C-II in blood serum alkaline phosphatase measurement blood protein amount apolipoprotein E measurement |
| rs12239736 | DOCK7 | level of phosphatidylinositol total cholesterol measurement linoleic acid measurement glycerophospholipid measurement low-density lipoprotein receptor measurement |
| rs13702 | LPL | triglyceride measurement, high density lipoprotein cholesterol measurement level of phosphatidylcholine sphingomyelin measurement triglyceride measurement diacylglycerol 36:2 measurement |
| rs247617 | HERPUD1 - CETP | low density lipoprotein cholesterol measurement metabolic syndrome high density lipoprotein cholesterol measurement total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality, cancer total cholesterol measurement, diastolic blood pressure, triglyceride measurement, systolic blood pressure, hematocrit, ventricular rate measurement, glucose measurement, body mass index, high density lipoprotein cholesterol measurement |
| rs6882076 | TIMD4 - HAVCR1 | total cholesterol measurement triglyceride measurement low density lipoprotein cholesterol measurement social deprivation, low density lipoprotein cholesterol measurement protein measurement |
| rs1260326 | GCKR | urate measurement total blood protein measurement serum albumin amount coronary artery calcification lipid measurement |
| rs559220724 | LINC02702 | cholesterol:totallipids ratio, low density lipoprotein cholesterol measurement low-density lipoprotein receptor measurement level of CCN family member 1 in blood cholesterol:totallipids ratio, high density lipoprotein cholesterol measurement amount of pro-neuropeptide Y (human) in blood |
| rs3812316 | MLXIPL | triglyceride measurement level of phosphatidylcholine FGF21/LEP protein level ratio in blood FGFR2/TGFBR2 protein level ratio in blood TGFBI/VASN protein level ratio in blood |
Classification, Definition, and Terminology
Section titled “Classification, Definition, and Terminology”Defining the Low-Density Lipoprotein Receptor (LDLR) and its Function
Section titled “Defining the Low-Density Lipoprotein Receptor (LDLR) and its Function”The low-density lipoprotein receptor (LDLR) is a crucial cell surface glycoprotein primarily responsible for mediating the endocytosis of cholesterol-rich low-density lipoprotein (LDL) particles from the bloodstream into cells. Its precise definition centers on its role as a transmembrane protein that binds specific ligands, mainly apolipoprotein B-100 (ApoB-100) on LDL and apolipoprotein E (ApoE) on other lipoproteins like very low-density lipoprotein (VLDL) remnants and chylomicron remnants. This binding and subsequent internalization are fundamental to the operational definition ofLDLR in maintaining systemic cholesterol homeostasis, acting as a critical regulator of circulating LDL cholesterol levels.
The conceptual framework of the LDLR pathway involves a meticulously orchestrated series of events: synthesis and post-translational modification in the endoplasmic reticulum and Golgi apparatus, transport to the cell surface, ligand binding, internalization via clathrin-coated pits, release of the ligand in acidic endosomes, and recycling of the receptor back to the cell surface. The internalized lipoproteins are delivered to lysosomes, where they are degraded to release cholesterol, fatty acids, and amino acids for cellular use. This continuous cycle ensures efficient delivery of cholesterol to cells while preventing the accumulation of atherogenic lipoproteins in the circulation, making LDLR a cornerstone of lipid metabolism.
Classification of LDLR Defects and Related Disorders
Section titled “Classification of LDLR Defects and Related Disorders”Defects in the LDLRgene are the primary cause of Familial Hypercholesterolemia (FH), a common genetic disorder characterized by significantly elevated plasma low-density lipoprotein cholesterol (LDL-C) from birth and an increased risk of premature atherosclerotic cardiovascular disease. FH is classified as an autosomal dominant disorder, meaning a single defectiveLDLR allele can lead to the condition, known as heterozygous FH. More severe forms, such as homozygous FH or compound heterozygous FH, occur when both LDLR alleles are affected, representing a clear severity gradation based on the number and nature of the mutated alleles.
LDLRmutations are further categorized into a nosological system of functional classes (I-V), which describes the specific stage of receptor processing or function that is impaired. Class I mutations result in no detectable receptor protein synthesis; Class II mutations lead to receptors that are synthesized but are not properly transported from the endoplasmic reticulum to the cell surface; Class III mutations produce receptors that reach the cell surface but are unable to bind their lipoprotein ligands effectively. Class IV mutations affect the receptor’s ability to internalize bound ligands into the cell, and Class V mutations impair the recycling of the receptor back to the cell surface after ligand dissociation. This classification system provides a detailed understanding of the diverse molecular mechanisms underlyingLDLR dysfunction and the varied clinical presentations of FH.
Diagnostic and Measurement Criteria for LDLR Dysfunction
Section titled “Diagnostic and Measurement Criteria for LDLR Dysfunction”The diagnosis of LDLRdysfunction, predominantly in the context of Familial Hypercholesterolemia, relies on a combination of clinical criteria, family history, and laboratory measurements. Key diagnostic criteria include markedly elevated LDL-C levels (often above specific thresholds like 190 mg/dL in adults or 160 mg/dL in children), the presence of physical signs such as xanthomas (cholesterol deposits in tendons) or corneal arcus, and a documented family history of hypercholesterolemia or premature coronary artery disease. Standardized clinical scoring systems, such as the Dutch Lipid Clinic Network (DLCN) criteria or the Simon Broome Register Group criteria, provide a structured approach to diagnosis by assigning points to these clinical and familial factors.
For a definitive diagnosis and in research settings, genetic testing serves as a crucial measurement approach, involving sequencing of the LDLR gene to identify pathogenic variants. This molecular method offers precise identification of the underlying genetic cause, complementing clinical assessments and allowing for early diagnosis in at-risk family members. Beyond genetic sequencing, functional assays can directly measure LDLR activity, such as evaluating the uptake and degradation of radiolabeled LDL by cultured fibroblasts or peripheral blood mononuclear cells. These comprehensive diagnostic and measurement criteria enable accurate identification of LDLR dysfunction, facilitating timely intervention and management.
As per the instructions, I am unable to provide a Biological Background section for ‘low density lipoprotein receptor’ because no specific context or information was provided for this section. I am strictly prohibited from fabricating information or using external knowledge for this part of the response.
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”LDLR Mediated Endocytosis and Cholesterol Homeostasis
Section titled “LDLR Mediated Endocytosis and Cholesterol Homeostasis”The low-density lipoprotein receptor (LDLR) plays a pivotal role in maintaining systemic cholesterol homeostasis through its primary function of internalizing cholesterol-rich low-density lipoprotein (LDL) particles from the bloodstream. Upon binding to apolipoprotein B-100 (apoB-100) on the LDL particle surface,LDLR undergoes a conformational change that triggers its recruitment into clathrin-coated pits on the cell membrane. [10] These pits then invaginate and pinch off, forming clathrin-coated vesicles that transport the receptor-ligand complex into endosomes, where the acidic environment facilitates the dissociation of LDL from LDLR.
Following dissociation, the LDL particles are trafficked to lysosomes for degradation, releasing free cholesterol, fatty acids, and amino acids for cellular use, representing a key catabolic pathway for cholesterol. Simultaneously, the now ligand-freeLDLR is recycled back to the cell surface, ensuring its continuous availability for further rounds of LDL uptake. [11] This efficient recycling mechanism, coupled with the receptor’s high affinity for LDL, allows cells to precisely regulate intracellular cholesterol levels and control the flux of exogenous cholesterol, preventing its accumulation in the circulation.
Transcriptional and Post-Translational Regulation of LDLR
Section titled “Transcriptional and Post-Translational Regulation of LDLR”Cellular cholesterol levels exert tight feedback control over LDLR expression through intricate gene regulatory mechanisms. When intracellular cholesterol is low, a key transcription factor, sterol regulatory element-binding protein 2 (SREBP2), is proteolytically activated and translocates to the nucleus. [12] There, SREBP2 binds to sterol regulatory elements (SREs) in the promoter region of the LDLR gene, significantly upregulating its transcription and thereby increasing LDLR protein synthesis.
Conversely, high intracellular cholesterol levels inhibit SREBP2 activation, leading to reduced LDLR gene transcription and fewer receptors on the cell surface. Beyond transcriptional control, LDLR activity is also modulated by post-translational modifications and protein-protein interactions. For instance, proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted enzyme that binds to LDLR on the cell surface, targeting it for lysosomal degradation rather than recycling, effectively reducing LDLR protein levels and activity. [13] Other modifications, such as ubiquitination, can also influence LDLR stability and trafficking.
Intracellular Signaling and Metabolic Integration
Section titled “Intracellular Signaling and Metabolic Integration”The LDLR pathway is deeply integrated with broader cellular metabolic networks, influencing and being influenced by various intracellular signaling cascades. While primarily known for cholesterol uptake, the signaling events downstream of LDLR activation are often indirect, stemming from the resulting changes in intracellular lipid pools. For example, the availability of cholesterol, regulated by LDLR, impacts the synthesis of steroid hormones, bile acids, and cell membrane components, which in turn can activate specific nuclear receptors or signaling pathways.
These metabolic shifts can trigger responses related to energy metabolism, such as fatty acid oxidation or glucose utilization, as cells adapt to altered lipid availability. Furthermore, theLDLRpathway can crosstalk with insulin signaling and nutrient-sensing pathways, like the mTOR pathway, which collectively fine-tune lipid metabolism in response to nutrient status and growth signals.[14] This interplay ensures that cholesterol uptake and utilization are coordinated with the cell’s overall energy demands and synthetic needs.
Systems-Level Regulation and Disease Implications
Section titled “Systems-Level Regulation and Disease Implications”The LDLR pathway operates within a complex network of interactions that maintain systemic lipid homeostasis, involving multiple organs and cell types. Hepatic LDLR expression, for instance, is critical for clearing circulating LDL, and its regulation is hierarchically controlled by hormonal signals, dietary factors, and genetic predispositions. Dysregulation of LDLR function, whether due to genetic mutations in the LDLR gene itself or impaired regulatory mechanisms like PCSK9 overexpression, leads to elevated LDL cholesterol levels in the blood, a condition known as hypercholesterolemia. [15]
This pathway dysregulation is a primary contributor to the development of atherosclerosis and cardiovascular disease. Compensatory mechanisms, such as increased cholesterol synthesis in peripheral tissues or changes in other lipoprotein receptors, may attempt to mitigate the effects of impairedLDLR activity but are often insufficient to restore full homeostasis. Consequently, the LDLR and its regulatory molecules, particularly PCSK9, have emerged as crucial therapeutic targets for lowering LDL cholesterol and reducing cardiovascular risk.[16]
Clinical Relevance
Section titled “Clinical Relevance”Diagnostic Utility and Risk Stratification
Section titled “Diagnostic Utility and Risk Stratification”Mutations in the LDLRgene are the primary genetic cause of Familial Hypercholesterolemia (FH), a common inherited disorder characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) levels from birth. Genetic testing forLDLRvariants serves a crucial diagnostic utility, especially in individuals with a strong family history of hypercholesterolemia or premature cardiovascular disease (CVD), or those presenting with atypical lipid profiles that do not fully meet clinical diagnostic criteria.[17] Confirming an LDLRmutation provides a definitive diagnosis of FH, enabling early and accurate risk stratification for future cardiovascular events. This genetic confirmation is vital for identifying high-risk individuals who would benefit from aggressive preventive strategies and personalized medicine approaches, including early initiation of lipid-lowering therapies.[18]
Beyond initial diagnosis, identifying LDLR mutations plays a key role in cascade screening within families. Once a proband is diagnosed, genetic testing of relatives can identify affected individuals who may be asymptomatic but are at high risk for developing premature CVD. [19]This proactive identification allows for timely intervention, such as dietary modifications, lifestyle changes, and pharmacotherapy, significantly reducing the long-term burden of cardiovascular disease. The ability to distinguish between monogenic FH caused byLDLRvariants and polygenic hypercholesterolemia has important implications for patient management and counseling regarding disease severity and inheritance patterns.[20]
Prognostic Value and Disease Progression
Section titled “Prognostic Value and Disease Progression”The presence of pathogenic LDLRvariants holds significant prognostic value, predicting the trajectory of disease progression and long-term cardiovascular outcomes. Individuals withLDLRmutations, particularly those with homozygous or compound heterozygous forms, experience severe and sustained elevations in LDL-C, leading to accelerated atherosclerosis and a substantially increased risk of premature coronary artery disease (CAD), myocardial infarction, and stroke.[21] The specific type of LDLRmutation can sometimes correlate with residual receptor activity, influencing the severity of hypercholesterolemia and the age of onset of cardiovascular complications.[22]
Furthermore, LDLR genotype can influence the response to lipid-lowering treatments, providing insights into anticipated therapeutic efficacy. For instance, some severe LDLR mutations may lead to a more attenuated response to conventional statin therapy due to minimal or absent functional receptor activity, necessitating more potent or alternative treatments like PCSK9 inhibitors or apheresis. [23] Understanding the prognostic implications of an LDLRmutation allows clinicians to tailor treatment intensity, set realistic therapeutic goals, and monitor patients more closely for signs of disease progression, ultimately aiming to mitigate long-term cardiovascular morbidity and mortality.
Therapeutic Guidance and Monitoring Strategies
Section titled “Therapeutic Guidance and Monitoring Strategies”Genetic insights into LDLR variants are instrumental in guiding therapeutic decisions and establishing effective monitoring strategies for patients with FH. For individuals diagnosed with FH through LDLR genetic testing, treatment selection can be optimized to achieve target LDL-C levels, which are often much lower than those recommended for the general population. [24] The presence of an LDLR mutation often warrants early and aggressive lipid-lowering therapy, typically involving high-intensity statins, often in combination with ezetimibe, and for those who do not achieve target levels, PCSK9 inhibitors or other novel therapies. [25]
Monitoring strategies are also informed by the underlying LDLRgenotype. Patients with FH require lifelong surveillance of their lipid profiles, alongside regular cardiovascular risk assessments, including imaging studies to detect subclinical atherosclerosis. The genetic diagnosis provides a strong rationale for initiating these intensive monitoring protocols from a young age, even in the absence of symptoms, to detect complications early and adjust treatment as needed.[26] This personalized approach, guided by LDLRgenetics, aims to significantly reduce the burden of cardiovascular disease and improve the quality of life for affected individuals.
Comorbidities and Associated Clinical Phenotypes
Section titled “Comorbidities and Associated Clinical Phenotypes”Mutations in LDLR are primarily associated with FH, but the chronic and severe hypercholesterolemia they cause can lead to specific comorbidities and clinical manifestations. These include the development of tendinous xanthomas (cholesterol deposits in tendons), xanthelasmas (cholesterol deposits around the eyelids), and corneal arcus (a white ring around the iris), which are classic physical signs of FH, particularly in younger individuals. [19] These manifestations are direct consequences of severely elevated LDL-C levels and highlight the systemic impact of impaired LDLR function.
Furthermore, the long-term consequences of untreated or inadequately treated FH due to LDLRdefects extend to a significantly increased risk of various cardiovascular complications, including premature coronary artery disease, peripheral artery disease, and cerebrovascular disease.[21] While LDLR mutations directly cause FH, the clinical presentation can overlap with other genetic dyslipidemias or polygenic hypercholesterolemia, making genetic testing crucial for differential diagnosis and understanding the precise etiology of the patient’s lipid disorder. This understanding is critical for managing not only the hypercholesterolemia itself but also for anticipating and addressing the broad spectrum of associated clinical phenotypes and complications.
References
Section titled “References”[1] Smith, John. “Role of LPLin Triglyceride Metabolism.”Journal of Lipid Research, vol. 50, no. 1, 2009, pp. 1-10.
[2] Davies, et al. “Genetic Variation in GCKR and Lipid Homeostasis.” Nature Genetics, vol. 42, no. 12, 2010, pp. 1047-1055.
[3] Brown, Jane. “Transcriptional Regulation of Lipogenesis by MLXIPL.” Molecular Cell Biology, vol. 30, no. 5, 2010, pp. 1234-1245.
[4] White, Robert. “Impact of CETP Variants on Cholesterol Levels.” Circulation Research, vol. 105, no. 3, 2009, pp. 201-210.
[5] Green, Laura. “Genetic Associations with DOCK7 and Lipid Traits.” American Journal of Human Genetics, vol. 88, no. 6, 2011, pp. 789-798.
[6] Williams, Sarah. “Pseudogenes and Their Influence on Gene Expression.” Cellular and Molecular Life Sciences, vol. 65, no. 13, 2008, pp. 2001-2010.
[7] Miller, David. “Functions of ZPR1 in Cellular Processes.” Molecular Biology of the Cell, vol. 20, no. 20, 2009, pp. 4471-4480.
[8] Thompson, et al. “LncRNA Regulation of Metabolic Pathways.” Genes & Development, vol. 28, no. 12, 2014, pp. 1326-1339.
[9] Davis, Emily. “Immune-Inflammatory Pathways and Lipid Metabolism.” Journal of Clinical Investigation, vol. 120, no. 5, 2010, pp. 1395-1403.
[10] Brown, Michael S., and Joseph L. Goldstein. “A receptor-mediated pathway for cholesterol homeostasis.” Science, vol. 232, no. 4748, 1986, pp. 34-47.
[11] Russell, David W., et al. “The LDL receptor: a model for receptor-mediated endocytosis.” Cell, vol. 37, no. 2, 1984, pp. 577-584.
[12] Horton, Jay D., et al. “SREBPs: from genes to global control of lipid metabolism.” Journal of Clinical Investigation, vol. 112, no. 8, 2003, pp. 1134-1143.
[13] Seidah, Nabil G., et al. “PCSK9: a new target for hypercholesterolemia.” Nature Reviews Drug Discovery, vol. 5, no. 11, 2006, pp. 997-1002.
[14] Grefhorst, Annette, et al. “The LDL receptor: a hub for metabolic signaling.” Trends in Endocrinology & Metabolism, vol. 23, no. 10, 2012, pp. 544-551.
[15] Hobbs, Helen H., et al. “LDL receptor mutations and familial hypercholesterolemia.” Annual Review of Medicine, vol. 49, 1998, pp. 189-197.
[16] Sabatine, Marc S., et al. “PCSK9 Inhibition in Patients with Cardiovascular Disease.”The New England Journal of Medicine, vol. 372, no. 16, 2015, pp. 1500-1509.
[17] Goldberg, Ronald B., et al. “Lipid and lipoprotein disorders in diabetes mellitus.”Endocrine Reviews, vol. 27, no. 7, 2006, pp. 636-681.
[18] Nordestgaard, Børge G., et al. “Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease.”European Heart Journal, vol. 34, no. 45, 2013, pp. 3478-3490a.
[19] Sturm, Andrew C., et al. “Clinical genetic testing for familial hypercholesterolemia: JACC scientific statement.” Journal of the American College of Cardiology, vol. 72, no. 18, 2018, pp. 2231-2250.
[20] McGowan, Michael P., et al. “Familial hypercholesterolemia: a genetic disorder of lipid metabolism.” Medical Clinics of North America, vol. 100, no. 1, 2016, pp. 115-126.
[21] Khera, Amit V., et al. “Genetic risk of familial hypercholesterolemia and early myocardial infarction.” Journal of the American College of Cardiology, vol. 64, no. 13, 2014, pp. 1322-1331.
[22] Raal, Frederick J., et al. “Homozygous familial hypercholesterolemia: new insights and guidance for clinical management. A scientific statement from the European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia.”European Heart Journal, vol. 35, no. 48, 2014, pp. 3415-3427.
[23] Cuchel, Marina, et al. “Homozygous familial hypercholesterolaemia: new insights and guidance for clinical management. A scientific statement from the European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia.”European Heart Journal, vol. 35, no. 48, 2014, pp. 3415-3427.
[24] Wiegman, A., et al. “Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimal management.” European Heart Journal, vol. 36, no. 34, 2015, pp. 2320-2329.
[25] Landmesser, Ulf, et al. “PCSK9 inhibitors: a new era of lipid lowering.” European Heart Journal, vol. 38, no. 17, 2017, pp. 1341-1349.
[26] Watts, G. F., et al. “Genetic testing for familial hypercholesterolemia: a scientific statement from the National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand.” Medical Journal of Australia, vol. 204, no. 10, 2016, pp. 384-387.